Aptar Pharma Multidose Device Delivers Approved Human Monoclonal Antibody Anti-COVID Nasal Spray in Thailand

Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announced that its VP7 nasal multidose device is the delivery system for Hibiocy’s VAILL COVITRAP™ Anti-CoV nasal spray, which was recently approved by the Thailand Food and Drug Administration (FDA).

The VAILL COVITRAP™ Anti-CoV nasal spray has been developed and classified as a medical device through the joint efforts of Chulalongkorn University, Silpakorn University, the Health Systems Research Institute (HSRI), the Government Pharmaceutical Organization (GPO) and Hibiocy Co. Ltd., an affiliate of Roujukiss International PCL (KISS).

The nasal spray using Aptar Pharma’s innovative VP7 multidose technology has been launched under the tradename “VAILL COVITRAP™ Anti- CoV Nasal Spray”, a hypromellose-based (HPMC) nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibodies. The formulation provides a physical barrier on nasal mucosa that could prevent and/or trap viral particles and aid in the defense against the virus.

“This approval by the Thailand FDA makes our VP7 multidose pump technology a key component of this Anti-Covid nasal spray and further demonstrates Aptar Pharma’s ability to help our customers develop and launch novel treatments that may help improve and save lives,” stated Alex Theodorakis, President, Aptar Pharma Prescription.

“The discovery behind the development of this innovative respiratory-care medical device with the human monoclonal antibody for inhibiting COVID-19 is critical, given the continuing concern of the virus impacting daily life. We are delighted to have the technology behind the VP7 multidose nasal spray pump from Aptar Pharma for our product, the VAILL COVITRAP™ Anti-CoV Nasal Spray,” said Worrawan Chaikamnerd, CEO at Hibiocy and KISS. “With proven technology, our product should be able to help protect patients from either becoming infected or reinfected with COVID-19.”

Aptar Pharma’s multidose VP7 nasal spray device is designed to enable reliable dosing and targeted medication delivery to the nasal mucosa and is used or in development for nasal drug delivery across a wide range of medical applications such as allergic rhinitis, pain and CNS, as well as intranasal antibodies, antivirals and vaccines.